Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.

Ejlertsen B, Jensen MB, Mouridsen HT; Danish Breast Cancer Cooperative Group..

Acta Oncol. 2014 Feb;53(2):174-85. doi: 10.3109/0284186X.2013.850738.

PMID:
24219541
2.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309.

3.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group..

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
4.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Breast International Group (BIG) 1-98 Collaborative Group., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.

N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].

6.

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.

Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B; Danish Breast Cancer Cooperative Group..

Eur J Cancer. 2014 May;50(8):1412-21. doi: 10.1016/j.ejca.2014.02.022.

PMID:
24675287
7.

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.

Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.

Cancer. 2008 Apr 1;112(7):1437-44. doi: 10.1002/cncr.23320.

8.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.

J Clin Oncol. 2007 Feb 10;25(5):486-92.

PMID:
17200148
9.

Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?

Aapro M, van de Velde CJ, Markopoulos C, Bartlett JM, Putter H, Coleman RE.

Breast. 2013 Aug;22(4):488-94. doi: 10.1016/j.breast.2013.01.007.

PMID:
23454040
11.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100.

12.

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.

J Clin Oncol. 2005 Aug 1;23(22):5178-87.

PMID:
15998905
13.

Selecting adjuvant endocrine therapy for breast cancer.

Eneman JD, Wood ME, Muss HB.

Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4. Review.

14.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
15.

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology.; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors.; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer..

J Natl Compr Canc Netw. 2006 Nov;4(10):971-9. Review.

PMID:
17112447
16.

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U.

Breast Cancer Res. 2010;12(4):R47. doi: 10.1186/bcr2604.

17.
18.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ; American Society of Clinical Oncology..

J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Review.

PMID:
20625130
19.

Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?

Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Kim B, Pillai A, Lawrenson R.

Breast. 2015 Feb;24(1):62-7. doi: 10.1016/j.breast.2014.11.011.

PMID:
25486877
20.

Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.

Simon R, Latreille J, Matte C, Desjardins P, Bergeron E.

Can J Surg. 2014 Feb;57(1):26-32.

Items per page

Supplemental Content

Support Center